Literature DB >> 17284292

Rapamycin: brain excitability studied in vitro.

Delchad Daoud1, Hans H Scheld, Erwin-Josef Speckmann, Ali Gorji.   

Abstract

Neurological complications are common in transplant recipients treated with immunosuppressant calcineurin inhibitors. Rapamycin, a macrolide antibiotic, was suggested as an alternative agent in patients who develop calcineurin inhibitor associated neurotoxicity, including seizure attacks. The aim of the present study was to test the effect of rapamycin on the bioelectrical activity and evoked field excitatory postsynaptic potentials (fEPSP) in CA1 area of hippocampal tissues and compare its effect with FK506, a calcineurin inhibitor agent. Application of rapamycin at different concentrations neither affected the bioelectrical activity nor changed fEPSP magnitude. In contrast, FK506 elicited epileptiform burst discharges and significantly enhanced fEPSP magnitude. This study supports the suggestion that rapamycin could be used as an alternative to calcineurin inhibitors in the event of neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17284292     DOI: 10.1111/j.1528-1167.2006.00976.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  A pulse rapamycin therapy for infantile spasms and associated cognitive decline.

Authors:  Emmanuel Raffo; Antonietta Coppola; Tomonori Ono; Stephen W Briggs; Aristea S Galanopoulou
Journal:  Neurobiol Dis       Date:  2011-04-12       Impact factor: 5.996

Review 2.  Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.

Authors:  Sharon S McDaniel; Michael Wong
Journal:  Neurosci Lett       Date:  2011-02-24       Impact factor: 3.046

3.  Rapamycin for treatment of epilepsy: antiseizure, antiepileptogenic, both, or neither?

Authors:  Michael Wong
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

Review 4.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 5.  Therapeutic approaches to epileptogenesis--hope on the horizon.

Authors:  Asla Pitkänen
Journal:  Epilepsia       Date:  2010-07       Impact factor: 5.864

6.  mTOR as a potential treatment target for epilepsy.

Authors:  Michael Wong
Journal:  Future Neurol       Date:  2012-09-01

7.  Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.

Authors:  Nicholas Rensing; Lirong Han; Michael Wong
Journal:  Epilepsia       Date:  2015-06-29       Impact factor: 5.864

8.  Pharmacological inhibition of the mammalian target of rapamycin pathway suppresses acquired epilepsy.

Authors:  Xiaoxing Huang; Hailong Zhang; Jun Yang; Jingfan Wu; John McMahon; Yufan Lin; Zhonglian Cao; Michael Gruenthal; Yunfei Huang
Journal:  Neurobiol Dis       Date:  2010-05-26       Impact factor: 5.996

9.  Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis.

Authors:  Mansoureh Togha; Mehrdad Jahanshahi; Leila Alizadeh; Soodeh Razeghi Jahromi; Gelareh Vakilzadeh; Bahram Alipour; Ali Gorji; Amir Ghaemi
Journal:  Mol Neurobiol       Date:  2016-03-12       Impact factor: 5.590

10.  Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain.

Authors:  Michael S Hester; Bethany E Hosford; Victor R Santos; Shatrunjai P Singh; Isaiah J Rolle; Candi L LaSarge; John P Liska; Norberto Garcia-Cairasco; Steve C Danzer
Journal:  Exp Neurol       Date:  2016-03-17       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.